TMS Co (TSE:4891) Ending Cash Position: 円0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4891 TMS Co Ltd TSE:4891
31 GF Score
Price 円109.00
! 1 Warning Sign
View Full Analysis

What is TMS Co Ending Cash Position?

TMS Co TSE:4891 -0.91% 31 Ending Cash Position is 円0.00 Mil as of Jun. 2026. GuruFocus rates TSE:4891 with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

TMS Co's Ending Cash Position for the quarter that ended in Jun. 2026 was 円0.00 Mil.

TMS Co's annual Ending Cash Position declined from Feb. 2023 (円3,584.67 Mil) to Feb. 2024 (円3,446.63 Mil) and declined from Feb. 2024 (円3,446.63 Mil) to Feb. 2025 (円2,922.95 Mil).

TMS Co Ending Cash Position Related Terms

TMS Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for TMS Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TMS Co Ending Cash Position Chart

TMS Co Annual Data
Trend Feb21 Feb22 Feb23 Feb24 Feb25
Ending Cash Position
1,106.69 2,598.00 3,584.67 3,446.63 2,922.95

TMS Co Quarterly Data
Feb21 Feb22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Feb25 May25 Aug25 Dec25 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4891
31GF Score
TMS Co Ltd TSE:4891
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TMS Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

TMS Co's Ending Cash Position for the fiscal year that ended in Feb. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=3446.63+-523.68
=2,922.95

TMS Co's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0+0
=0.00

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of 円0.00 Mil mean?
TMS Co (TSE:4891) has a Ending Cash Position of 円0.00 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on TMS Co and its competitors.
Is TMS Co's Ending Cash Position too high?
TMS Co's current Ending Cash Position is 円0.00 Mil. Overall, TMS Co has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does TMS Co's Ending Cash Position compare to VRTX and REGN?
TMS Co's Ending Cash Position of 円0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on TMS Co and its competitors. TMS Co's current Ending Cash Position is 円0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TMS Co stock overvalued right now?
TMS Co (TSE:4891) has a current Ending Cash Position of 円0.00 Mil. The current Ending Cash Position is 円0.00 Mil. TMS Co's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For TMS Co (TSE:4891), the current Ending Cash Position is 円0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TMS Co Business Description

Address 1-9-11F, Fuchu-cho, Fuchu-shi, Tokyo, JPN, 183-0055
TMS Co Ltd is focused on researching, developing, manufacturing, and selling pharmaceuticals. The company is involved in conducting research and development of SMTP compounds, which are drug candidate substances targeting soluble epoxide hydrolase (sEH), an enzyme found in the human body. It is developing sEH inhibitors for various inflammatory diseases. The company's clinical pipeline comprises three compounds: TMS-007 (being developed as a potential treatment for acute cerebral infarction), which is in the late clinical stage, TMS-010, and JX09 (for resistant and poorly controlled hypertension) and TMS-008 (to target acute inflammatory diseases such as kidney injury and cancer cachexia), which are in the early clinical stage. In addition, it has TMS-009 as a backup compound for TMS-008.
31GF Score

Get the complete analysis for TSE:4891

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円109.00
Price